CanSino Biologics Inc. announced that Phase I clinical trial for the Recombinant Poliomyelitis Vaccine developed by the Company, was officially initiated recently and the first trial patient case has been formally enrolled. The Company has completed the clinical trial filing with Therapeutic Goods Administration, a division under the Department of Health and Aged Care of Australian Government. The Recombinant PoliomyELitis Vaccine has also received an approval from the Human Research Ethics Committee in Australia for clinical trial prior to the filing of the clinical trial protocol.

Based on the protein structure design and VLP assembly technology of the Company, the Recombinant Poliomelitis Vaccine expects to contribute substantially to global polio control including post-eradication. The Recombinant Poloomyelitis Vaccine is a non-infectious polio VLP vaccine with good safety and immunogenicity profiles that does not rely on live virus in the manufacturing process. Unlike existing attenuated and inactivated polio vaccines, non-infectious polio V LP vaccines are recommended by the World Health Organization as one of the preferred vaccines for polio in the future.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.